Navigation Links
Can we get there from here? Translating stem cell research into therapies
Date:5/25/2011

A new article published by Cell Press in the May 26 issue of the journal Neuron provides comprehensive insight into the current status of neural stem cell research and the sometimes labyrinthine pathways leading to stem cell-based therapies. The perspective on translating neural stem cell research into clinical therapeutics is part of a special issue of Neuron devoted to neural stem cells and neurogenesis and is published in collaboration with the May issue of Cell Stem Cell, which also has a selection of reviews on this topic.

Neurological disease and injury are a major cause of disability worldwide, and there is a pressing need to find reparative therapeutics for the central nervous system (CNS). Although stem cell therapies represent the frontier of regenerative medicine, the "bench to bedside" leap where scientific discoveries in the laboratory are translated to actual patient therapeutics faces many challenging hurdles.

"Stem cell research is one of the most rapidly developing areas of science and medicine," says study author Dr. Sally Temple from the Neural Stem Cell Institute in Rensselaer, New York. "The explosive rise in discoveries and technologies that we see in the basic research labs has yet to enter the pipeline, and there is an enormous gap between what we can do at the bench and what we see in the current clinical trials. It is imperative that we work towards making the process of translation more effective and affordable."

In their article, Dr. Temple and colleagues describe the current status of stem cell-based CNS therapies, analyze currently approved clinical trials, and discuss key issues associated with translational progress. The authors report that many basic scientists are struggling with low funding levels and that funding cutbacks substantially impede new research directions. They suggest that successfully transitioning from the lab to the clinics requires a comprehensive and collaborative team effort among researchers, clinicians, regulatory agencies, patient advocacy groups, ethics bodies, and industry, and they stress that pioneering this new partnership model is essential for smooth translational path that will improve the chance that the health benefits of research reach patients.

"There is no doubt that stem cell research and application is opening great opportunities in CNS regenerative therapies and, although our survey shows that we are still at relatively early stages of defining safety for human trials, stupendous strides are being made in preclinical studies," says Dr. Temple. "However, we must engage basic researchers and their institutions to ensure that they participate in the rewards of successful translation and benefit from revenue return that will fund further creative discoveries. We envision a much more concerted effort towards translation that would make the process more accessible and efficient, forging new private/public partnerships that will spread both risks and benefits in the process. Ultimately, the rewards of solving this problem could be seen at every level, from the next generation of young scientists to the patients. We need to take steps soon, as the challenge posed by neurological disorders is growing."


'/>"/>

Contact: Elisabeth Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology news :

1. Mating rivalry among furred and feathered: Variety is spice of life
2. Secret lives of the furred and feathered
3. Species unique to single island should not be rare there
4. Unknown animals nearly invisible but yet there
5. Macavity wasnt there! How absent reoviruses kill cancer
6. Theres a new officer in the infection control army
7. Urban gardeners beware: There may be lead in your soil and food
8. Why are there no hyenas in Europe?
9. Are there too many stem cell journals?
10. Scientists show theres nothing boring about watching paint dry
11. For pandas, there is a mountain high enough, there is a valley low enough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... RESEARCH TRIANGLE PARK, N.C. , April 27, 2017 ... ) today announced that its Board of Directors authorized ... company,s common stock. This program will became effective immediately, ... may be made in the open market, accelerated share ... time as determined by United Therapeutics, management and in ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is ... ) is coming to San Diego, CA on September 27-28, 2017. Leaders from ... the latest advances in the treatment of various types of pain. There are ...
(Date:4/27/2017)... ... 2017 , ... The Council for Agricultural Science and Technology ... a consummate communicator who promotes agricultural science and technology in the public arena. ... how innovation and growth in agriculture are critical for food security and global ...
(Date:4/26/2017)... USA (PRWEB) , ... April 26, 2017 , ... ... on FDA’s GMP expectations for phase I clinical trials comes to Tampa, San ... various biotechnology and pharma professionals representing FDA regulated organizations such as Pfizer Inc., ...
Breaking Biology Technology: